Ht-Logo-gigapixel-icon
Ht-Logo-gigapixel-icon
Sunday, February 23, 2025

Canada’s Politics and Government News Source Since 1989

Latest Paper
Sunday, February 23, 2025 | Latest Paper
Subscribe Now

TRENDING:

Matthew Herder and Srinivas Murthy

Matthew Herder and Srinivas Murthy

A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada

  • The $925-million public-private partnership to enhance the manufacturing capacity of Sanofi’s influenza vaccine facility in Toronto is only the latest in a string of
Opinion | BY MATTHEW HERDER AND SRINIVAS MURTHY | April 19, 2021
A woman, pictured July 20, 2020, walking down Wellington Street in Ottawa. Before COVID-19, industry had shown little interest in developing treatments against coronaviruses. This led many to suggest that we should rethink how we encourage biopharmaceutical innovation for public health emergencies. The Hill Times photograph by Andrew Meade

A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada

Opinion | BY MATTHEW HERDER AND SRINIVAS MURTHY | April 19, 2021
  • The $925-million public-private partnership to enhance the manufacturing capacity of Sanofi’s influenza vaccine facility in Toronto is only the latest in a string of

A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada

Opinion | BY MATTHEW HERDER AND SRINIVAS MURTHY | April 19, 2021
  • The $925-million public-private partnership to enhance the manufacturing capacity of Sanofi’s influenza vaccine facility in Toronto is only the latest in a string of
A woman, pictured July 20, 2020, walking down Wellington Street in Ottawa. Before COVID-19, industry had shown little interest in developing treatments against coronaviruses. This led many to suggest that we should rethink how we encourage biopharmaceutical innovation for public health emergencies. The Hill Times photograph by Andrew Meade
More Stories

News

Get free news updates

Opinion

Submit a guest opinion article

resources

Follow us

Advertise

get help

Subscribe
CloseMenu